Why we choose fenofibrate? Fenofibrate in long-term therapy – larger packages, greater benefits for patients with atherogenic dyslipidemia Review article

Article Sidebar

Requires Subscription PDF (Język Polski)


Published: Jun 30, 2025
DOI: https://doi.org/10.24292/01.MF.0225.18
Keywords:
therapeutic adherence, atherogenic dyslipidemia, metabolic syndrome, type 2 diabetes

Main Article Content

Marcin Wełnicki
III Klinika Chorób Wewnętrznych i Kardiologii, Wydział Lekarski, Warszawski Uniwersytet Medyczny

Abstract

Fenofibrate remains an important drug in the treatment of dyslipidemia – the molecule of choice for severe hypertriglyceridemia, as well as a key drug in optimizing the pharmacotherapy of atherogenic dyslipidemia, especially in patients with type 2 diabetes. According to polish experts, when additional TG reduction is indicated in patients already taking a statin, the rationale for using a fibrate instead of omega-3 fatty acids is, among other things, practical considerations – the drug’s availability, simple dosing regimen, and affordable price. All these factors favor therapeutic adherence, which is also improved by the drug’s availability in multi-tablet packages. These seemingly trivial, yet very practical factors complement the value of a molecule with very beneficial pleiotropic effects, crucial especially in the presence of metabolic disorders.

Article Details

How to Cite
Wełnicki, M. (2025). Why we choose fenofibrate? Fenofibrate in long-term therapy – larger packages, greater benefits for patients with atherogenic dyslipidemia. Medycyna Faktow (J EBM), 18(2(67), 290-292. https://doi.org/10.24292/01.MF.0225.18
Issue
Vol 18 No 2(67) (2025)
Section
Articles

Copyright © by Medical Education. All rights reserved.

References

1. Okopień B, Bułdak Ł, Bołdys A. Fibraty. In: Lipidologia. Mamcarz A, Barylski M, Wełnicki M (eds). PZWL, Warszawa 2021.
2. Leczenie zaburzeń lipidowych w codziennej praktyce klinicznej. Mamcarz A, Folga D, Śliż M et al. (eds). Medical Tribune Polska, Warszawa 2020.
3. Wełnicki M, Gorczyca-Głowacka I, Kapłon-Cieślicka A et al. Treatment of dyslipidemia in Poland – common diagnostics, early combined therapy. Expert position statement endorsed by the Polish Cardiac Society Working Group on Cardiovascular Pharmacotherapy. 5th Declaration of Sopot. Cardiol J. 2025; 32(2): 107-19. https://doi.org/10.5603/cj.103680.
4. Mach F, Baigent C, Catapano AL et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020; 41(1): 111-188. http://doi.org/10.1093/eurheartj/ehz455.
5. Banach M, Burchardt P, Chlebus K et al. PoLA/CFPiP/PCS/PSLD/PSD/PSH guidelines on diagnosis and therapy of lipid disorders in Poland 2021. Arch Med Sci 2021; 17: 1447. https://doi.org/10.5114/AOMS/141941.
6. Action to Control Cardiovascular Risk in Diabetes Study Group; Gerstein HC, Miller ME, Byington RP et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008; 358(24): 2545-59. https://doi.org/10.1056/NEJMoa0802743.
7. Zhu L, Hayen A, Bell KJL. Legacy effect of fibrate add-on therapy in diabetic patients with dyslipidemia: a secondary analysis of the ACCORDION study. Cardiovasc Diabetol. 2020; 19(1): 28. https://doi.org/10.1186/s12933-020-01002-x.
8. Dobrowolski P, Prejbisz A, Szyndler A et al. Physician-patient partnership – can it help increase adherence to the therapeutic recommendations in cardiovascular disease? Arterial Hypertens. 2024 ; 28 : 50-70. http://doi.org/10.5603/ah.103488.
9. Taitel M, Fensterheim L, Kirkham H et al. Medication Days’ Supply, Adherence, Wastage, and Cost Among Chronic Patients in Medicaid. Medicare Medicaid Res Rev. 2012; 2(3): mmrr.002.03.a04. http://dx.doi.org/10.5600/mmrr.002.03.a04.